X4 Pharmaceuticals, Inc XFOR
We take great care to ensure that the data presented and summarized in this overview for X4 Pharmaceuticals, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XFOR
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$7.95 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$7.04 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$5.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$3.85 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$3.44 Million2.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$3.35 Million0.15% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY4.94MShares$2.32 Million0.62% of portfolio
-
Geode Capital Management, LLC Boston, MA3.5MShares$1.64 Million0.0% of portfolio
-
Axa S.A. Paris, I03.07MShares$1.44 Million0.01% of portfolio
-
State Street Corp Boston, MA3.06MShares$1.44 Million0.0% of portfolio
Latest Institutional Activity in XFOR
Top Purchases
Top Sells
About XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Insider Transactions at XFOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2025
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
650,000
+36.29%
|
-
|
|
Feb 12
2025
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+45.14%
|
-
|
|
Feb 12
2025
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,250,000
+40.27%
|
-
|
|
Feb 12
2025
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+50.0%
|
-
|
|
Feb 12
2025
|
Christophe Arbet Engels Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+49.59%
|
-
|
|
Jan 24
2025
|
Christophe Arbet Engels Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,624
-45.0%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
22,258
-4.34%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
29,159
-23.65%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
74,773
-100.0%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
76,473
-6.57%
|
$0
$0.45 P/Share
|
|
Jan 23
2025
|
Christophe Arbet Engels Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,831
+50.0%
|
-
|
|
Jan 23
2025
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,178
+10.65%
|
-
|
|
Jan 23
2025
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,773
+37.75%
|
-
|
|
Jan 23
2025
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,773
+50.0%
|
-
|
|
Jan 23
2025
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
169,940
+12.74%
|
-
|
|
Nov 15
2024
|
Mark Baldry Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
13,404
+9.4%
|
$0
$0.34 P/Share
|
|
Nov 15
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
31,897
-3.11%
|
$0
$0.39 P/Share
|
|
Oct 15
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
31,897
-3.02%
|
$0
$0.56 P/Share
|
|
Oct 07
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230,645
-100.0%
|
$0
$0.55 P/Share
|
|
Oct 07
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
76,920
-16.54%
|
$0
$0.56 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 7.23M shares |
|---|---|
| Open market or private purchase | 35.1K shares |
| Open market or private sale | 1.04M shares |
|---|